financetom
Business
financetom
/
Business
/
Digital subscription platform MarketWise Q3 revenue declines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Digital subscription platform MarketWise Q3 revenue declines
Nov 6, 2025 3:17 PM

Overview

* MarketWise Q3 2025 revenue declines year-over-year, net income at $17.9 mln

* Billings for Q3 2025 increase 30% year-over-year, reflecting strong demand

* Company announces $0.40 per share dividend, including special dividend

Outlook

* MarketWise ( MKTW ) expects FY 2025 Billings to be approximately $260 mln

* Company's preliminary target for FY 2026 Billings is approximately $290 mln

* MarketWise ( MKTW ) preliminary FY 2026 projection for CFFO is $45 mln, a 50% YoY increase

Result Drivers

* STRATEGIC PRICING - Co attributes 30% YoY increase in Billings to strategic pricing adjustments and attracting serious investors

* HIGHER ARPU - Increase in average revenue per user contributed to improved margins despite decline in paid subscribers

* CFFO IMPROVEMENT - Cash from operating activities improved, impacted by IT expenditures recorded in prepaid assets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $81.30

Revenue mln

Q3 Net $17.90

Income mln

Q3 $63.70

Billings mln

Q3 $2.20

Operatin mln

g Cash

Flow

Analyst Coverage

* The one available analyst rating on the shares is "hold"

* The average consensus recommendation for the professional information services peer group is "buy."

* Wall Street's median 12-month price target for MarketWise Inc ( MKTW ) is $20.00, about 15.8% above its November 5 closing price of $16.84

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Skechers Usa Insider Sold Shares Worth $1,905,968, According to a Recent SEC Filing
Skechers Usa Insider Sold Shares Worth $1,905,968, According to a Recent SEC Filing
Mar 5, 2024
04:57 PM EST, 03/05/2024 (MT Newswires) -- Robert Greenberg, 10% Owner, Director, Chief Executive Officer, on March 01, 2024, sold 31,202 shares in Skechers Usa ( SKX ) for $1,905,968. Following the Form 4 filing with the SEC, Greenberg has control over a total of 136,617 shares of the company, with 132,783 shares held directly and 3,834 controlled indirectly. SEC...
Orthofix Medical Q4 Loss Widens, Sales Rise; 2024 Sales Outlook Set
Orthofix Medical Q4 Loss Widens, Sales Rise; 2024 Sales Outlook Set
Mar 5, 2024
04:57 PM EST, 03/05/2024 (MT Newswires) -- Orthofix Medical ( OFIX ) reported a Q4 loss late Tuesday of $0.59 per diluted share, wider than a loss of $0.35 a year earlier. Four analysts surveyed by Capital IQ expected a loss of $0.49. Net sales for the quarter ended Dec. 31 were $200.4 million, up from $122.2 million a year...
Irhythm Technologies Insider Sold Shares Worth $360,983, According to a Recent SEC Filing
Irhythm Technologies Insider Sold Shares Worth $360,983, According to a Recent SEC Filing
Mar 5, 2024
04:56 PM EST, 03/05/2024 (MT Newswires) -- Mark J. Day, Chief Technology Officer, on March 04, 2024, sold 3,248 shares in Irhythm Technologies ( IRTC ) for $360,983. Following the Form 4 filing with the SEC, Day has control over a total of 61,164 shares of the company, with 61,164 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1388658/000138865824000061/xslF345X03/wk-form4_1709675551.xml Price: 108.25, Change: +0.82,...
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing
Mar 5, 2024
04:56 PM EST, 03/05/2024 (MT Newswires) -- Sarah Boyce, Director, President and CEO, on March 01, 2024, sold 84,000 shares in Avidity Biosciences ( RNA ) for $1,691,306. Following the Form 4 filing with the SEC, Boyce has control over a total of 112,117 shares of the company, with 112,117 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1599901/000159990124000038/xslF345X03/wk-form4_1709675574.xml Price: 19.52, Change: +0.38,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved